Prognostic biomarkers for immunotherapy with ipilimumab in metastatic melanoma

por Nyakas, M., Aamdal, E., Jacobsen, K. D., Guren, T. K., Aamdal, S., Hagene, K. T., Brunsvig, P., Yndestad, A., Halvorsen, B., Tasken, K. A., Aukrust, P., Mælandsmo, G. M., Ueland, T.
Publicado 2019

Health-related quality of life in patients with advanced melanoma treated with ipilimumab: prognostic implications and changes during treatment

por Aamdal, E., Skovlund, E., Jacobsen, K.D., Straume, O., Kersten, C., Herlofsen, O., Karlsen, J., Hussain, I., Amundsen, A., Dalhaug, A., Nyakas, M., Hagene, K.T., Holmsen, K., Aamdal, S., Kaasa, S., Guren, T.K., Kyte, J.A.
Publicado 2022

A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma

por Piperno-Neumann, S., Carlino, M. S., Boni, V., Loirat, D., Speetjens, F. M., Park, J. J., Calvo, E., Carvajal, R. D., Nyakas, M., Gonzalez-Maffe, J., Zhu, X., Shirley, M. D., Ramkumar, T., Fessehatsion, A., Burks, H. E., Yerramilli-Rao, P., Kapiteijn, E.
Publicado 2023

Phase I study of saracatinib (AZD0530) in combination with paclitaxel and/or carboplatin in patients with solid tumours

por Kaye, S, Aamdal, S, Jones, R, Freyer, G, Pujade-Lauraine, E, de Vries, E G E, Barriuso, J, Sandhu, S, Tan, D S-W, Hartog, V, Kuenen, B, Ruijter, R, Kristensen, G B, Nyakas, M, Barrett, S, Burke, W, Pietersma, D, Stuart, M, Emeribe, U, Boven, E
Publicado 2012